Does INFLIXIMAB Cause Bladder transitional cell carcinoma? 63 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 63 reports of Bladder transitional cell carcinoma have been filed in association with INFLIXIMAB (Renflexis). This represents 0.0% of all adverse event reports for INFLIXIMAB.
63
Reports of Bladder transitional cell carcinoma with INFLIXIMAB
0.0%
of all INFLIXIMAB reports
0
Deaths
53
Hospitalizations
How Dangerous Is Bladder transitional cell carcinoma From INFLIXIMAB?
Of the 63 reports, 53 (84.1%) required hospitalization, and 2 (3.2%) were considered life-threatening.
Is Bladder transitional cell carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB. However, 63 reports have been filed with the FAERS database.
What Other Side Effects Does INFLIXIMAB Cause?
Off label use (34,801)
Drug ineffective (33,738)
Condition aggravated (16,616)
Rheumatoid arthritis (16,251)
Pain (15,061)
Fatigue (13,473)
Arthralgia (13,441)
Infusion related reaction (12,946)
Product use issue (12,752)
Drug intolerance (11,173)
What Other Drugs Cause Bladder transitional cell carcinoma?
PIOGLITAZONE (398)
ADALIMUMAB (96)
METHOTREXATE (95)
RITUXIMAB (74)
TOCILIZUMAB (68)
SULFASALAZINE (55)
HYDROXYCHLOROQUINE (50)
PREDNISONE (48)
LENALIDOMIDE (42)
RANITIDINE (41)
Which INFLIXIMAB Alternatives Have Lower Bladder transitional cell carcinoma Risk?
INFLIXIMAB vs INFLIXIMAB-ABDA
INFLIXIMAB vs INFLIXIMAB-AXXQ
INFLIXIMAB vs INFLIXIMAB-DYYB
INFLIXIMAB vs INFLIXIMAB-QBTX
INFLIXIMAB vs INFLIXIMAB, RECOMBINANT